Stifel Nicolaus Forecasts Strong Price Appreciation for Edwards Lifesciences (NYSE:EW) Stock

Edwards Lifesciences (NYSE:EW) had its target price boosted by equities research analysts at Stifel Nicolaus from $100.00 to $105.00 in a report issued on Wednesday, Marketbeat.com reports. The firm currently has a “buy” rating on the medical research company’s stock. Stifel Nicolaus’ price target indicates a potential upside of 24.19% from the company’s previous close.

EW has been the subject of a number of other reports. Canaccord Genuity Group set a $87.00 price target on Edwards Lifesciences and gave the company a “hold” rating in a research report on Wednesday, December 17th. Raymond James Financial raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price objective on the stock in a research note on Monday, November 3rd. Sanford C. Bernstein restated a “market perform” rating and issued a $90.00 target price on shares of Edwards Lifesciences in a report on Monday, November 3rd. National Bankshares set a $92.00 target price on Edwards Lifesciences in a research note on Friday, October 31st. Finally, Piper Sandler reissued an “overweight” rating and set a $95.00 price target (up previously from $90.00) on shares of Edwards Lifesciences in a research report on Friday, October 31st. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $94.27.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $84.55 on Wednesday. The company has a fifty day simple moving average of $85.01 and a 200-day simple moving average of $80.25. The firm has a market capitalization of $49.06 billion, a price-to-earnings ratio of 36.44, a PEG ratio of 3.45 and a beta of 0.95. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a 52-week low of $65.94 and a 52-week high of $87.89.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The firm had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same period in the previous year, the business posted $0.67 earnings per share. Edwards Lifesciences’s quarterly revenue was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. On average, equities analysts anticipate that Edwards Lifesciences will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling

In other news, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $84.03, for a total value of $85,626.57. Following the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at approximately $1,848,828.06. The trade was a 4.43% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Scott B. Ullem sold 7,700 shares of the company’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $84.47, for a total transaction of $650,419.00. Following the completion of the transaction, the chief financial officer owned 39,898 shares in the company, valued at approximately $3,370,184.06. This represents a 16.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 56,805 shares of company stock valued at $4,775,995. 1.29% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Edwards Lifesciences

Several large investors have recently added to or reduced their stakes in the business. JPL Wealth Management LLC purchased a new position in Edwards Lifesciences in the 3rd quarter valued at approximately $25,000. Rosenberg Matthew Hamilton acquired a new stake in shares of Edwards Lifesciences in the second quarter valued at $28,000. True Wealth Design LLC boosted its holdings in Edwards Lifesciences by 251.5% in the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 259 shares during the period. NewSquare Capital LLC boosted its holdings in Edwards Lifesciences by 57.8% in the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 134 shares during the period. Finally, Hantz Financial Services Inc. grew its stake in Edwards Lifesciences by 76.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock worth $29,000 after purchasing an additional 164 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.